Adherence to pegylated combination therapy in patients with chronic hepatitis C.: Importance of the trio hepatologist, general practitioner, nurse

被引:5
|
作者
Wartelle-Bladou, C. [1 ,2 ]
Rosenthal, E. [3 ]
Ratziu, V. [4 ]
De Ledinghen, V. [5 ]
Lang, J. -P. [6 ]
Poynard, T. [4 ]
机构
[1] Ctr Hosp Pays Aix, Serv Hepatogastroenterol, F-13616 Aix En Provence 1, France
[2] Reseau Sante Prov, F-13770 Venelles, France
[3] Hop Archet 1, Serv Med Interne, F-06202 Nice 3, France
[4] Hop La Pitie Salpetriere, Serv Hepatogastroenterol, F-75013 Paris, France
[5] Hop Haut Leveque, Serv Hepatogastroenterol, F-33600 Pessac, France
[6] Ctr Hosp Erstein, F-67152 Erstein, France
来源
关键词
hepatitis C; compliance; general practitioner; ribavirin; peginterferon alpha-2b; peginterferon alpha-2a;
D O I
10.1016/S0399-8320(08)73272-X
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Adhesion to pegylated combination therapy is a key factor for therapeutic success in patients HCV infected. To optimize it, goats to reach are to limit dose reduction and premature discontinuation of treatment due to adverse events; to improve the patient compliance to treatment, particularly during the first three months, particularly to ribavirin. Therapeutic education, management of psychiatric adverse events, epoetin alfa, have demonstrated their benefit in terms of sustained virologic response or quality of life. Preparing the treatment with the patient and a multi-disciplinary team, setting successive therapeutic goals with the predictive value of the early virologic response will promote adhesion to treatment. A hepatitis C training program for general practitioners (GP) allows an efficient follow-up of treated patients by a trio hepatologist - GP -nurse and a concrete implication of GP in the field of hepatitis C. Further developments are needed for : taking in account the patient quality of life during treatment to anticipate premature discontinuation, promotion of therapeutic education by specialized nurses, standardization of the diagnosis of depression during treatment, and regular updating of general practitioners on antiviral C treatment (C) 2008 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:S96 / S108
页数:13
相关论文
共 50 条
  • [31] Endogenous hematopoietic response during combination therapy in patients with hepatitis C.
    Kreil, A
    Wichlas, M
    Hofer, H
    Homoncik, M
    Gangl, A
    Ferenci, P
    Peck-Radosavljevic, M
    HEPATOLOGY, 2002, 36 (04) : 601A - 601A
  • [32] Induction treatment with combination therapy results in a lower relapse rate in naive patients with chronic hepatitis C.
    Rothstein, KD
    Pena, RE
    Suvannasankha, A
    DiGregorio, K
    Manzarbeitia, C
    Reich, DJ
    Bond, K
    Gross, F
    Shaw, E
    Peikin, S
    Mushnick, A
    Munoz, SJ
    HEPATOLOGY, 2000, 32 (04) : 560A - 560A
  • [33] Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan
    Oze, Tsugiko
    Hiramatsu, Naoki
    Yakushijin, Takayuki
    Mochizuki, Kiyoshi
    Oshita, Masahide
    Hagiwara, Hideki
    Mita, Eiji
    Ito, Toshifumi
    Inui, Yoshiaki
    Fukui, Hiroyuki
    Hijioka, Taizo
    Katayama, Kazuhiro
    Tamura, Shinji
    Yoshihara, Harumasa
    Inoue, Atsuo
    Imai, Yasuharu
    Hayashi, Eijiro
    Kato, Michio
    Hosui, Atsushi
    Miyagi, Takuya
    Ishida, Hisashi
    Yoshida, Yuichi
    Tatsumi, Tomohide
    Kiso, Shinichi
    Kanto, Tatsuya
    Kasahara, Akinori
    Takehara, Tetsuo
    Hayashi, Norio
    JOURNAL OF GASTROENTEROLOGY, 2011, 46 (08) : 1031 - 1037
  • [34] Serum KL-6 level is elevated in chronic hepatitis C patients with combination therapy of pegylated interferon and ribavirin
    Arase, Yasuji
    Ikeda, Kenji
    Suzuki, Yoshiyuki
    Kobayashi, Masahiro
    Suzuki, Fumitaka
    Akuta, Norio
    Sezaki, Hitomi
    Hosaka, Tetsuya
    Yatsuji, Hiromi
    Kawamura, Yusuke
    Kobayashi, Mariko
    Kumada, Hiromitsu
    INTERNAL MEDICINE, 2007, 46 (15) : 1155 - 1159
  • [35] Incidence of retinopathy in chronic Hepatitis C patients treated with pegylated interferon alpha 2a and ribavirin combination therapy
    Kashif, Muhammad
    Saleem, Muhammad Khurram
    Farooka, Imran Khan
    Husnain, Amino
    Siddiqui, Arif Mahmood
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2015, 31 (01) : 174 - 177
  • [36] The impact of thyroid autoantibodies on the treatment response to pegylated interferon plus ribavirin combination therapy in chronic hepatitis C patients
    Huang, C. K.
    Dai, C. Y.
    Huang, J. F.
    Hsieh, M. Y.
    Hou, N. J.
    Lin, W. Y.
    Lin, Z. Y.
    Chen, S. C.
    Wang, L. Y.
    Chuang, W. L.
    Yu, M. L.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 : A187 - A187
  • [37] Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan
    Tsugiko Oze
    Naoki Hiramatsu
    Takayuki Yakushijin
    Kiyoshi Mochizuki
    Masahide Oshita
    Hideki Hagiwara
    Eiji Mita
    Toshifumi Ito
    Yoshiaki Inui
    Hiroyuki Fukui
    Taizo Hijioka
    Kazuhiro Katayama
    Shinji Tamura
    Harumasa Yoshihara
    Atsuo Inoue
    Yasuharu Imai
    Eijiro Hayashi
    Michio Kato
    Atsushi Hosui
    Takuya Miyagi
    Hisashi Ishida
    Yuichi Yoshida
    Tomohide Tatsumi
    Shinichi Kiso
    Tatsuya Kanto
    Akinori Kasahara
    Tetsuo Takehara
    Norio Hayashi
    Journal of Gastroenterology, 2011, 46 : 1031 - 1037
  • [38] Impact of Ribavirin Dosage in Chronic Hepatitis C Patients Treated With Simeprevir, Pegylated Interferon Plus Ribavirin Combination Therapy
    Tahata, Yuki
    Hiramatsu, Naoki
    Oze, Tsugiko
    Urabe, Ayako
    Morishita, Naoki
    Yamada, Ryoko
    Yakushijin, Takayuki
    Hosui, Atsushi
    Oshita, Masahide
    Kaneko, Akira
    Hagiwara, Hideki
    Mita, Eiji
    Ito, Toshifumi
    Yamada, Yukinori
    Inada, Masami
    Katayama, Kazuhiro
    Tamura, Shinji
    Imai, Yasuharu
    Hikita, Hayato
    Sakamori, Ryotaro
    Yoshida, Yuichi
    Tatsumi, Tomohide
    Hayashi, Norio
    Takehara, Tetsuo
    JOURNAL OF MEDICAL VIROLOGY, 2016, 88 (10) : 1776 - 1784
  • [39] Studies of therapy with thymosin α1 in combination with pegylated interferon α2a and ribavirin in nonresponder patients with chronic hepatitis C
    Camerini, Roberto
    Ciancio, Alessia
    De Rosa, Alfonso
    Rizzetto, Mario
    THYMOSINS IN HEALTH AND DISEASE: FIRST INTERNATIONAL SYMPOSIUM, 2007, 1112 : 368 - 374
  • [40] Retinol Supplements Antiviral Action of Pegylated Interferon and Ribavirin Combination Therapy in Patients With Chronic Hepatitis C: Prospective Pilot
    Sato, Shuichi
    Kohge, Naruaki
    Uchida, Yasushi
    Miyake, Tatsuya
    Tobita, Hiroshi
    Ishine, Junichi
    Hanaoka, Takuya
    Amano, Yuji
    Kinoshita, Yoshikazu
    GASTROENTEROLOGY, 2010, 138 (05) : S847 - S847